Personally Identifiable Information
Novocure collects personally identifiable information (information that can be used to identify an individual) such as name, address, telephone number, email address or other information only when you voluntarily submit it to Novocure, such as when you email a question or request or submit a form for more information. Novocure will use this information to respond to requests for information and may use this information to contact you and provide you with information about our products. Novocure may also request that you provide us with demographic information (such as gender and age) or other information (such as medical condition or treatment information) that Novocure uses to help serve you better.
Non-Personally Identifiable Information
Novocure may also collect non-personally identifiable information (information that does not identify a specific individual) relating to such matters as: the number of visits to the website, the number of visitors to each page of the website, visitors' internet protocol (IP) addresses, and time spent on the website. Novocure uses this information, in aggregate form, to understand how visitors use the website so that Novocure can make improvements. Novocure may also use your IP address to help diagnose problems with servers and for purposes of system administration.
We may partner with other companies to provide or offer you content or services on a joint or cobranded basis. At a cobranded site or in joint marketing materials, you would likely see both the Novocure logo and the logo of the cobranded partner displayed on your screen. To access the services available on a cobranded site, you may have to complete a new online registration form, and this registration information may be shared with Novocure and Novocure's cobranded partners. You should read the individual privacy policies of our cobranded partners, as these may differ in some respects from ours. Reading these policies will help you to make an informed decision about whether to provide your information to a given site. You may opt out of sharing your information with a partner site by choosing not to use the service or content provided by the cobranded site.
To the extent permitted by law, any personally identifiable information or other information collected over our website or concerning its use, including the content of any communication you submit or post to any interactive features on the website (personally identifiable or not), may be disclosed to government authorities or third parties pursuant to a governmental investigation, legal request, subpoena, or other legal process. We also may share information with the government even without a request pursuant to regulatory reporting requirements. In addition, we may also use or disclose your information as permitted by law to enforce our rights, fight fraud, or protect the rights or property of Novocure, our affiliates, our patients, our website, its users, or third parties, or when we otherwise believe in good faith that the law requires it.
Corporate Change of Control or Sale of Assets
In the event of a corporate change in control resulting from, for example, a sale to or merger with another entity, or in the event of a sale of assets or a bankruptcy, Novocure reserves the right to transfer your personally identifiable information to the new party in control or the party acquiring assets.
Novocure does not knowingly collect any personal information from anyone under the age of 18, nor does Novocure knowingly market its website to anyone under the age of 18.
Please be advised that although Novocure has tried to create a secure and reliable site, the confidentiality of any communication or material transmitted to or from this website cannot be guaranteed. Novocure urges you to always exercise caution when conveying personal information over the internet.
When disclosing any personally identifiable information, you should remain mindful that such information might be accessible by the public and, consequently, may be collected and used by others without your consent. You should also recognize that your use of the internet and this site is solely at your own risk.
Questions or Concerns
If you have other questions or concerns about our privacy policies or information usage, or wish to change any choices offered about how your information is handled or shared, email us at firstname.lastname@example.org.
Effective Date: April 7, 2014
Optune is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.
If you have newly diagnosed GBM, Optune is used together with a chemotherapy called temozolomide (TMZ) if:
If your tumor has come back, Optune can be used alone as an alternative to standard medical therapy if:
Optune is not for everyone. Talk to your doctor if you have:
Do not use Optune if you are pregnant or are planning to become pregnant. It is not known if Optune is safe or effective during pregnancy.
Optune should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure™, the maker of Optune.
Most common side effects of Optune when used together with chemotherapy (temozolomide, or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, scalp irritation from the device, headache, seizure, and depression.
The most common side effects when using Optune alone were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers.
Talk to your doctor if you have any of these side effects or questions.
Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.
On this site, patient and healthcare professional videos as well as all images labeled as Optune users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals. All other depictions of patients and caregivers are actor portrayals.
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).